hVIVO plc (AIM: HVO), a pioneer of human disease models and an industry leading clinical development and drug discovery services business, is pleased to announce that all resolutions proposed at its Annual General Meeting, held at 10.00am on 23 May 2018, were duly passed.

For further information please contact:

hVIVO plc

Trevor Phillips (Executive Chairman)

Fleur Wood (Director, Investor Relations)

+44 207 756 1300
Numis Securities Limited +44 207 260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)

James Black / Michael Burke (Corporate Broking)

FTI Consulting
Simon Conway / Victoria Foster Mitchell
 +44 203 727 1000

Notes to Editors:

hVIVO plc ('hVIVO') is pioneering a human-based analytical platform to accelerate drug discovery and development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV and asthma exacerbation, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 50 clinical studies, inoculated over 2500 volunteers and has three first-in-class therapies currently in development with a growing pre-clinical pipeline.

Attachments

  • Original document
  • Permalink

Disclaimer

IP Group plc published this content on 23 May 2018 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 23 May 2018 16:27:13 UTC